| 纯度 | > 80 % SDS-PAGE. |
| 种属 | Human |
| 靶点 | BEX1 |
| Uniprot No | Q9HBH7 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-125aa |
| 氨基酸序列 | MGSSHHHHHHSSGLVPRGSHMGSMESKEKRAVNSLSMENANQENEEKEQV ANKGEPLALPLDAGEYCVPRGNRRRFRVRQPILQYRWDMMHRLGEPQARM REENMERIGEEVRQLMEKLREKQLSHSLRAVSTDPPHHDHHDEFCLMP |
| 预测分子量 | 17 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于BEX1重组蛋白的示例参考文献(内容为示例，实际引用需查阅真实文献)：
---
1. **文献名称**：*BEX1重组蛋白通过抑制NF-κB通路调控胶质母细胞瘤的凋亡*
**作者**：Li, X., et al.
**摘要**：研究证明BEX1重组蛋白在胶质母细胞瘤细胞中过表达可显著抑制NF-κB信号通路活性，诱导肿瘤细胞凋亡并抑制增殖，提示其作为潜在治疗靶点。
2. **文献名称**：*重组人BEX1蛋白促进神经干细胞分化的机制研究*
**作者**：Wang, Y., et al.
**摘要**：通过体外实验发现，BEX1重组蛋白通过激活Wnt/β-catenin通路，促进神经干细胞向神经元分化，为神经再生治疗提供新策略。
3. **文献名称**：*BEX1重组蛋白在乳腺癌中的抑癌功能及临床意义*
**作者**：Smith, J., et al.
**摘要**：临床样本分析结合体外实验表明，BEX1重组蛋白通过下调EGFR表达抑制乳腺癌转移，其低表达与患者预后不良相关。
4. **文献名称**：*高效表达与纯化BEX1重组蛋白的工艺优化*
**作者**：Zhang, R., et al.
**摘要**：报道了一种利用大肠杆菌表达系统高效制备BEX1重组蛋白的方法，并通过质谱验证其结构正确性，为后续功能研究奠定基础。
---
**提示**：以上为模拟文献，实际研究中请通过PubMed、Web of Science或Google Scholar等平台检索真实文献(关键词如“BEX1 recombinant protein”或“BEX1 function”)。
BEX1 (Brain Expressed X-linked protein 1) is a member of the BEX/TAX family of small adaptor proteins, initially identified for its high expression in the brain and involvement in neuronal development. It plays regulatory roles in cell proliferation, differentiation, apoptosis, and intracellular signaling pathways, particularly through interactions with neurotrophin receptors like TrkB. BEX1’s expression is not limited to neural tissues; it has been implicated in various cancers, where it may act as either a tumor suppressor or promoter depending on context. For instance, BEX1 downregulation is linked to poor prognosis in gliomas, while its overexpression in breast or lung cancers correlates with aggressive phenotypes.
Recombinant BEX1 protein is engineered using genetic cloning techniques, often expressed in *E. coli* or mammalian cell systems to preserve functional domains. This purified protein enables researchers to study BEX1’s molecular mechanisms, such as its role in modulating NF-κB, MAPK, or Wnt signaling cascades. It also serves as a tool for *in vitro* binding assays, cellular uptake studies, or therapeutic exploration, including potential applications in neuroregeneration or cancer immunotherapy. Challenges in BEX1 research include its context-dependent dual roles and unresolved structural dynamics. Current studies focus on optimizing recombinant BEX1 production, elucidating its post-translational modifications, and evaluating its diagnostic or therapeutic potential in precision medicine.
×
